Skip to main content

Table 1 Clinical characteristics of the cohort according to prophylaxis received

From: Perioperative prophylaxis with ertapenem reduced infections caused by extended-spectrum betalactamase-producting Enterobacteriaceae after kidney transplantation

Variable

Cefazolin (n = 110)

Ertapenem (n = 113)

P

Age in years (mean, ±SD)

54.02 (13.6)

53.99 (14.7)

1

Male sex

61 (55%)

65 (57%)

0.7

Donor type

 Deceased

53 (48%)

61 (54%)

0.4

 Live

57 (52%)

52 (46%)

Donor’s cause of death

 Anoxia

14 (26%)

8 (15%)

0.1

 CVA

31 (58%)

42 (80%)

 Trauma

7 (13%)

2 (4%)

 Other

1 (2%)

0

Median ischemia time (minutes, ±SD)

473 (470)

491 (434)

0.4

Diabetes mellitus

24 (22%)

26 (23%)

0.8

End-stage renal disease

 Glomerulonephritis

9 (8%)

6 (5%)

0.9

 Diabetes mellitus

17 (16%)

17 (16%)

 Hypertension

19 (17%)

16 (14%)

 Cystic kidney disease

18 (16%)

17 (15%)

 Other Urologic

8 (7%)

10 (9%)

 Other cause

23 (21%)

23 (20%)

 Unkown/missing

16 (15%)

24 (21%)

Prior transplantation

18 (16%)

22 (19%)

0.6

Immunosuppression regimen

 CNI + MMF+ CS

72 (65%)

64 (57%)

0.3

 CNI + mTOR+ CS

34 (31%)

46 (41%)

 Other

4 (4%)

3 (2%)

Induction

 None

18 (16%)

9 (8%)

0.4

 Basiliximab

26 (24%)

55 (49%)

 Anti-lymphocyte globulines

66 (60%)

49 (43%)

Pre-transplant rituximab

13 (12%)

13 (11%)

0.9

  1. CVA Cerebrovascular accident, CNI Calcineurin inhibitors, MMF Mycophenolate mofetil, mTOR Inhibitors of mammalian target of rapamycin, CS Corticosteroids